Market Cap : 956.48 M | Enterprise Value : 745.93 M | PE Ratio : | PB Ratio : 4.86 |
---|
NAS:GTHX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:GTHX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, G1 Therapeutics's enterprise value is $745.93 Mil. G1 Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Sep. 2020 was $-114.18 Mil. Therefore, G1 Therapeutics's EV-to-EBITDA for today is -6.53.
During the past 5 years, the highest EV-to-EBITDA of G1 Therapeutics was -1.80. The lowest was -8.40. And the median was -3.60.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2021-02-24), G1 Therapeutics's stock price is $25.140000. G1 Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2020 was $-2.90. Therefore, G1 Therapeutics's PE Ratio for today is .
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.
* The bar in red indicates where G1 Therapeutics's EV-to-EBITDA falls into.
G1 Therapeutics's EV-to-EBITDA for today is calculated as:
EV-to-EBITDA | = | Enterprise Value (Today) | / | EBITDA (TTM) |
= | 745.934 | / | -114.184 | |
= | -6.53 |
G1 Therapeutics's current Enterprise Value is $745.93 Mil.
G1 Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Sep. 2020 was -41.894 (Dec. 2019 ) + -31.662 (Mar. 2020 ) + -30.787 (Jun. 2020 ) + -9.841 (Sep. 2020 ) = $-114.18 Mil.
* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
G1 Therapeutics's PE Ratio for today is calculated as:
PE Ratio | = | Share Price (Today) | / | Earnings per Share (Diluted) (TTM) |
= | 25.140000 | / | -2.9 | |
= |
G1 Therapeutics's share price for today is $25.140000.
G1 Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2020 was -0.94 (Dec. 2019 ) + -0.82 (Mar. 2020 ) + -0.83 (Jun. 2020 ) + -0.31 (Sep. 2020 ) = $-2.90.
* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Please read Which price ratio outperforms the enterprise multiple?
No Headline